Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35918   clinical trials with a EudraCT protocol, of which   5893   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-000184-40
    Sponsor's Protocol Code Number:20130173
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2014-09-01
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-000184-40
    A.3Full title of the trial
    Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and
    Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Estudio prospectivo, multicéntrico y de un solo brazo para evaluar la eficacia, seguridad y farmacocinética de denosumab en niños con osteogénesis imperfecta
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Estudio para evaluar la eficacia, seguridad y farmacocinética de denosumab en niños con osteogénesis imperfecta
    A.4.1Sponsor's protocol code number20130173
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/086/2013
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAmgen, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAmgen Inc
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAmgen (Europe) GmbH
    B.5.2Functional name of contact pointIHQ-Medical Info - Clinical Trials
    B.5.3 Address:
    B.5.3.1Street AddressDammstrasse 23, P.O Box 1557
    B.5.3.2Town/ cityZug
    B.5.3.3Post codeCH-6300
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number900850153
    B.5.6E-mailMedinfoInternational@amgen.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name XGEVA
    D.2.1.1.2Name of the Marketing Authorisation holderAmgen Europe B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDenosumab
    D.3.2Product code AMG 162
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDenosumab
    D.3.9.1CAS number 615258-40-7
    D.3.9.2Current sponsor codeAMG 162
    D.3.9.3Other descriptive nameDenosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand
    D.3.9.4EV Substance CodeSUB29173
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number70
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Osteogenesis Imperfecta
    Osteogénesis imperfecta
    E.1.1.1Medical condition in easily understood language
    Osteogenesis Imperfecta
    Osteogénesis imperfecta
    E.1.1.2Therapeutic area Diseases [C] - Musculoskeletal Diseases [C05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level PT
    E.1.2Classification code 10031243
    E.1.2Term Osteogenesis imperfecta
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score at 12 months, as assessed by dual-energy X-ray absorptiometry (DXA), in children 2 to 17 years of age with osteogenesis imperfecta (OI).
    Evaluar el efecto de denosumab en la puntuación Z de la densidad mineral ósea (DMO) de la columna lumbar a los 12 meses, evaluada mediante absorciometría por rayos
    X de energía dual (DXA), en niños de 2 a 17 años de edad con osteogénesis imperfecta (OI).
    E.2.2Secondary objectives of the trial
    To evaluate denosumab in children 2 to 17 years of age with OI with
    respect to:
    - Change in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24, and 36 months
    - Change in proximal femur BMD Z-score, as assessed by DXA, at 6, 12, 18, 24, and 36 months
    - Incidence of new and worsening fractures (x-ray confirmed long bone and vertebral fractures) from pre-treatment to post-treatment at 12, 24, and 36 months
    - Incidence of improving vertebral fractures from pre-treatment to post-treatment at 12, 24, and 36 months (overall, among subjects with clinical fracture reduction, and among subjects with clinical fracture increase)
    - Incidence of pre-treatment compared with post-treatment vertebral and nonvertebral fractures at 12, 24, and 36 months
    + Exploratory and Safety objectives
    For complete list, please refer to the protocol
    -Cambio en la puntuación Z de la DMO de la columna lumbar, evaluada mediante DXA, a
    los 6, 18, 24 y 36 meses.
    -Cambio en la puntuación Z de la DMO del fémur proximal, evaluada mediante DXA, a los
    6, 12, 18, 24 y 36 meses.
    -Incidencia de fracturas nuevas y empeoradas (fracturas de huesos largos y vertebrales
    confirmadas mediante radiografías) desde antes del tratamiento hasta los 12, 24 y 36
    meses después del tratamiento.
    -Incidencia de la mejora de las fracturas vertebrales desde antes del tratamiento hasta los
    12, 24 y 36 meses después del tratamiento (global, entre los sujetos con reducción de
    las fracturas clínicas y entre los sujetos con aumento de las fracturas clínicas).
    -Incidencia de fracturas vertebrales y no vertebrales antes del tratamiento en
    comparación con después del tratamiento a los 12, 24 y 36 meses.
    Para el resto de objetivos secundarios ver protocolo.?
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PK/bone turnover markers (BTM) substudy of approximately 50 subjects to
    - determine serum concentration of denosumab at 1 and 10 days and 6, 12, 18, 24, 30, and 36 months in all subjects
    - evaluate changes observed in bone turnover markers (bone-specific alkaline phosphatase [BSAP], serum type I collagen C-telopeptide [sCTX])
    PK/marcadores de remodelado óseo [BTM] con aproximadamente 50 sujetos para determinar la concentración sérica de denosumab al cabo de 1 y 10 días y a los 6, 12, 18, 24, 30 y 36 meses en todos los sujetos.
    Evaluar cambio en los marcadores de remodelado óseo (fosfatasa alcalina específica del hueso [BSAP], C-telopéptido del colágeno tipo 1 sérico [sCTX]).
    E.3Principal inclusion criteria
    -Informed consent (to be provided by parent or legal guardian) and informed assent (to be provided by subjects when age-appropriate).
    -Children aged 2 to 17 years inclusive at screening
    -Clinical diagnosis of OI defined as a clinical history consistent with type I-IV OI as determined by presence of expected phenotype (examples include: facial shape, voice, blue sclera, dentinogenesis imperfecta, typical radiographic features, fracture pattern) and lack of additional features unrelated to type I-IV OI (eg, blindness, mental retardation, neuropathy, craniosynostosis; premature exfoliation of deciduous teeth)
    ?* If familial, also must be autosomal dominant
    - Clinical severity of OI as defined by
    o 2 or more prevalent vertebral compression fractures; OR
    o 1 prevalent vertebral compression fracture and 1 or more nonvertebral fractures within the previous 2 years; OR
    o 3 or more fractures within the previous 2 years
    .El representante legal autorizado del sujeto ha dado su consentimiento informado cuando el sujeto es legalmente demasiado joven para dar su
    consentimiento informado y el sujeto ha dado su conformidad por escrito de acuerdo con las normativas y/o directrices locales antes de iniciar cualquier
    actividad/procedimiento específico del estudio.
    .Niños de 2 a 17 años de edad, ambos incluidos, en el momento de la selección.
    .Diagnóstico clínico de OI, definido como una historia clínica que coincide con la de OI de tipo I-IV, determinada por la presencia del fenotipo esperado (ejemplos: forma facial, voz, esclerótica azul, dentinogénesis imperfecta, características
    radiográficas típicas, patrón de fractura) y la falta de características adicionales
    no relacionadas con la OI de tipo I-IV (p. ej., ceguera, retraso mental, neuropatía,craneosinostosis; exfoliación prematura de los dientes de leche de aspecto
    normal).
    ? -Si es familiar, también debe ser autosómica dominante.
    .La gravedad clínica de la OI se define como
    - 2 o más fracturas por compresión vertebral prevalentes;
    - 1 fractura por compresión vertebral prevalente y 1 o más fracturas no vertebrales en los 2 años previos; O
    - 3 o más fracturas en los 2 años previos.
    E.4Principal exclusion criteria
    Subjects meeting any of the following criteria at screening are not eligible for enrollment:
    - Inability or unwillingness to comply with the requirements for frequent calcium and phosphorus monitoring for 14 days after the first dose of denosumab (only applies to the first 5 subjects age 11 to17 enrolled in the study and the first 5 subjects of any age meeting the criteria for increased bone turnover (see Section 2.3.2.1)
    - Currently unhealed fracture or osteotomy as defined by orthopedic opinion
    - Osteotomy within 5 months of screening
    - Evidence of untreated oral cavities or oral infections
    - Recent or planned invasive dental procedure
    - Surgical tooth extraction which has not healed by screening
    - History of an electrophoresis pattern inconsistent with type I to IV OI
    - History of genetic testing results inconsistent with type I to IV OI
    - Abnormalities of the following per central laboratory reference ranges at screening:
    o Serum albumin corrected calcium < lower limit of normal (LLN)
    o Serum vitamin D < 30 ng/mL; re-screening for Vitamin D level
    < 30 ng/mL will be allowed, after adequate supplementation
    o Aspartate aminotransferase (AST), alanine aminotransferase (ALT)
    > 1.5 x upper limit of normal (ULN)
    o Total bilirubin (TBL) > 1.5 x ULN (subjects with Gilbert syndrome are
    eligible)
    o Serum phosphorus < LLN
    o Serum alkaline phosphatase > 20% above the ULN or > 20% below the
    LLN
    - Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 (calculated by the Schwartz equation at screening)
    - Evidence of any of the following:
    o Current hyperthyroidism (unless well-controlled on stable antithyroid
    therapy)
    o Current clinical hypothyroidism (unless well-controlled on stable thyroid replacement therapy)
    o History of hyperparathyroidism
    o Current hypoparathyroidism
    o Current, uncontrolled hypercalcemia (albumin-corrected serum Ca >10% ULN)
    o Current metaphyseal index Z-score > +1
    o History of osteomalacia or rickets (chart review)
    o Other bone diseases that affect bone metabolism (eg, osteoporosis
    pseudoglioma syndrome, idiopathic juvenile osteoporosis, osteopetrosis, hypophosphatasia)
    o History of autoimmune disease
    o History of malabsorption (in children with serum albumin < LLN,
    malabsorption should be clinically ruled out by the PI to confirm eligibility)
    o History of rare hereditary problems of fructose intolerance
    o History of long QT syndrome
    o History of non-healing osteotomy
    o History of malignancy
    o History of alcohol or drug abuse
    o History of any solid organ or bone marrow transplant
    o Contraindicated or poorly tolerant of denosumab therapy
    - Positive blood screen for human immunodeficiency virus -1 or -2
    antibody
    - Positive blood screen for hepatitis B surface antigen or hepatitis C antibody
    - Currently pregnant or planning a pregnancy during the study and for an additional 5 months after the last dose of denosumab
    - For sexually active girls: refusal to use acceptable methods of contraception and to continue this practice for 5 months after the last injection of denosumab
    -Incapacidad o falta de voluntad de cumplir los requisitos de supervisión frecuente del calcio y el fósforo durante 14 días tras la primera dosis de denosumab (solo se aplica a los primeros 5 sujetos de entre 11 y 17 años incluidos en el estudio y a los primeros 5 sujetos de cualquier edad que cumplan los criterios de aumento del remodelado óseo (consulte el apartado 2.3.2.1).
    -Presencia actual de fractura u osteotomía no consolidadas según criterio ortopédico.
    -Osteotomía en los 5 meses anteriores a la selección.
    -Evidencia de cavidades orales o infecciones orales no tratadas.
    -Procedimiento dental invasivo reciente o planeado.
    -Extracción dental quirúrgica que no se ha curado en el momento de la selección.
    -Antecedentes de un patrón de electroforesis incompatible con la OI de tipo I a IV.
    -Antecedentes de resultados de pruebas genéticas incompatibles con la OI de tipo I a IV.
    -Calcio corregido por albúmina sérica < límite inferior de la normalidad (LIN).
    -Vitamina D sérica < 30 ng/mL; se podrá volver a realizar la reselección por nivel de vitamina D < 30 ng/mL después de la suplementación adecuada.
    -Aspartato aminotransferasa (AST) o alanina aminotransferasa (ALT) > 1,5 x el límite superior de la normalidad (LSN).
    -Bilirrubina total (BiT) > 1,5 x LSN (los sujetos con síndrome de Gilbert son elegibles).
    -Fósforo sérico < LIN.
    -Fosfatasa alcalina sérica > 20% por encima del LSN o > 20% por debajo del LIN.
    -Tasa de filtración glomerular estimada (eGFR) < 60 mL/min/1,73 m2 (calculada con la ecuación de Schwartz en el momento de la selección).
    Evidencia de cualquiera de las siguientes situaciones:
    -Hipertiroidismo actual (a no ser que esté bien controlado con tratamiento antitiroideo estable).
    -Hipotiroidismo clínico actual (a no ser que esté bien controlado con tratamiento de sustitución tiroidea estable).
    -Antecedentes de hiperparatiroidismo.
    -Hipoparatiroidismo actual.
    -Hipercalcemia incontrolada actual (Ca sérico corregido por albúmina > 10% del LSN).
    -Puntuación Z del índice metafisario actual > + 1.
    -Antecedentes de osteomalacia o raquitismo (revisión de la historia clínica).
    -Otras enfermedades óseas que afectan al metabolismo óseo (por ejemplo, síndrome de osteoporosis-pseudoglioma, osteoporosis juvenil idiopática, osteopetrosis e hipofosfatasia) (revisión de la historia clínica).
    -Antecedentes de enfermedad autoinmune.
    -Antecedentes de malabsorción (en niños con albúmina sérica < LIN; la malabsorción debe ser descartada clínicamente por el investigador para confirmar la elegibilidad).
    -Antecedentes de problemas hereditarios raros de intolerancia a la fructosa
    -Antecedentes de síndrome de QT largo.
    -Antecedentes de osteotomía no consolidada.
    -Antecedentes de neoplasias malignas.
    -Antecedentes de alcoholismo o drogadicción.
    -Antecedentes de trasplantes de órganos sólidos o de médula ósea.
    -Contraindicaciones o mala tolerancia al tratamiento con denosumab.
    -Análisis de sangre positivo para anticuerpos frente al virus de la inmunodeficiencia humana de tipo 1 o 2
    -Análisis de sangre positive para anticuerpos frente al antigen de superficie de la hepatitis B o frente a la hepatitis C.
    -Embarazo actual o planificación de embarazo durante el estudio y durante los 5 meses adicionales después de la última dosis de denosumab.
    -Lactancia actual o planificación de dar el pecho durante el estudio y durante los 5 meses adicionales después de la última dosis de denosumab.
    -En el caso de las chicas sexualmente activas: rechazo a utilizar métodos anticonceptivos aceptables y a seguir utilizándolos durante los 5 meses posteriores a la última inyección de denosumab.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 12 months.
    Cambio respecto al valor basal en la puntuación Z de la DMO de la columna
    lumbar, evaluada mediante DXA, a los 12 meses.
    E.5.1.1Timepoint(s) of evaluation of this end point
    at 12 months
    A los 12 meses
    E.5.2Secondary end point(s)
    - Change from baseline in lumbar spine BMD Z-score, as assessed by DXA, at 6, 18, 24, and 36 months
    - Change from baseline in proximal femur BMD Z-score, as assessed by DXA, at 6, 12, 18, 24, and 36 months
    - Subject incidence of new and worsening fractures (x-ray confirmed long bone and vertebral fractures) at 12, 24, and 36 months compared to pre-treatment
    - Subject incidence of improved vertebral fractures at 12, 24, and 36 months compared to pre-treatment
    - Subject incidence of vertebral and nonvertebral fractures at 12, 24, and 36 months compared to pre-treatment
    - Change from baseline in CHQ-PF-50 Physical Summary score at 12, 24, and 36 months
    - Change from baseline in CHQ-PF-50 Psychological Summary score at 12, 24, and 36 months
    - Change from baseline in CHAQ Disability Index score at 12, 24, and 36 months
    - Change from baseline in WBFPRS at 12, 24, and 36 months
    - Change from baseline in growth velocity (determined by calculating age-adjusted Z-scores for height, weight and BMI) at 36 months
    - Serum concentration of denosumab at 1 and 10 days, and 6, 12, 18, 24, 30, and 36 months
    - Serum concentration of denosumab at 1, 10, and 30 days, and 3, 6, 12, 18, 24, 30, and 36 months (PK/BTM substudy only)
    -Cambio respecto al valor basal en la puntuación Z de la DMO de la columna lumbar,
    evaluada mediante DXA, a los 6, 18, 24 y 36 meses.
    -Cambio respecto al valor basal en la puntuación Z de la DMO del fémur proximal,
    evaluada mediante DXA, a los 6, 12, 18, 24 y 36 meses.
    -Incidencia en los sujetos de fracturas nuevas y empeoradas (fracturas de huesos largos y vertebrales confirmadas mediante radiografías) a los 12, 24 y 36 meses en comparación con antes del tratamiento.
    -Incidencia en los sujetos de la mejora de las fracturas vertebrales a los 12, 24 y 36
    meses en comparación con antes del tratamiento.
    -Incidencia en los sujetos de fracturas vertebrales y no vertebrales a los 12, 24 y 36 meses en comparación con antes del tratamiento.
    -Cambio respecto al valor basal en la puntuación del resumen físico del cuestionario CHQ-PF-50 a los 12, 24 y 36 meses.
    -Cambio respecto al valor basal en la puntuación del resumen psicológico del cuestionario CHQ-PF-50 a los 12, 24 y 36 meses.
    -Cambio respecto al valor basal en la puntuación del índice de discapacidad CHAQ a los 12, 24 y 36 meses.
    -Cambio respecto al valor basal en la escala WBFPRS a los 12, 24 y 36 meses.
    -Cambio respecto al valor basal en la velocidad de crecimiento (determinada mediante el
    cálculo de las puntuaciones Z ajustadas por edad para la altura, el peso y el índice de
    masa corporal [IMC]) a los 36 meses.
    -Concentración sérica de denosumab al cabo de 1 y 10 días, y a los 6, 12, 18, 24, 30 y 36
    meses.
    -Concentración sérica de denosumab al cabo de 1, 10 y 30 días, y a los 3, 6, 12, 18, 24, 30 y 36 meses (solo en el subestudio de PK/BTM).
    E.5.2.1Timepoint(s) of evaluation of this end point
    see list above
    Ver la lista de arriba punto E 5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Bulgaria
    Canada
    Czech Republic
    Finland
    France
    Germany
    Hungary
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    the end of the trial is defined when all enrolled subjects are given the
    opportunity to be followed for approximately 3 years for the purposes of final collection of data for the final analysis. ( LPLV)
    El fin del ensayo se define como el momento en que se ofrece a todos
    los sujetos incluidos la oportunidad de someterse a seguimiento durante
    aproximadamente 3 años con la finalidad de recoger los datos para el análisis final.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 150
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 80
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 70
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 94
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-10-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-10-15
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA